Related Experiment Video
Updated: Jun 2, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer
1Department of Medicine, Tulane Medical School, New Orleans, LA 70115, USA. osartor@tulane.edu
Abstract:
Genetic heterogeneity and chemotherapy-resistant 'stem cells' represent two of the most pressing issues in devising new strategies for the treatment of advanced prostate cancer. Though curative strategies have long been present for men with localized disease, metastatic prostate cancer is currently incurable. Though substantial improvements in outcomes are now possible through the utilization of newly approved therapies, novel combinations are clearly needed. Herein we describe potentially synergistic interactions between bone stromal-targeted radiopharmaceuticals and other therapies for treatment of bone-metastatic prostate cancer. Radiation has long been known to synergize with cytotoxic chemotherapies and recent data also suggest the possibility of synergy when combining radiation and immune-based strategies. Combination therapies will be required to substantially improve survival for men with castrate-resistant metastatic prostate cancer and we hypothesize that bone-targeted radiopharmaceuticals will play an important role in this process.
Insights
New strategies are needed for advanced prostate cancer, which is currently incurable. Bone-targeted radiopharmaceuticals may synergize with other treatments to improve survival for metastatic prostate cancer patients.
Area of Science:
- Oncology
- Nuclear Medicine
- Cancer Therapeutics
Background:
- Advanced prostate cancer, particularly metastatic disease, remains incurable despite advances.
- Genetic heterogeneity and chemotherapy-resistant stem cells pose significant challenges in treatment.
- Current therapies offer improvements but novel combinations are essential for castrate-resistant metastatic prostate cancer.
Purpose of the Study:
- To explore potential synergistic interactions between bone stromal-targeted radiopharmaceuticals and other therapeutic modalities.
- To investigate novel combination strategies for treating bone-metastatic prostate cancer.
Main Methods:
- Review of existing literature on radiation synergy with chemotherapy and immunotherapy.
- Hypothesizing the role of bone-targeted radiopharmaceuticals in combination therapies.
Main Results:
- Radiation is known to synergize with cytotoxic chemotherapies.
- Emerging data suggest synergy between radiation and immune-based strategies.
- Bone-targeted radiopharmaceuticals offer a promising approach for combination therapy in bone metastases.
Conclusions:
- Combination therapies are crucial for improving survival in castrate-resistant metastatic prostate cancer.
- Bone-targeted radiopharmaceuticals are hypothesized to play a key role in future treatment regimens.
- Synergistic interactions between bone-targeted radiopharmaceuticals and other therapies warrant further investigation.
